Wiskott-Aldrich syndrome gene therapy - Genethon

Drug Profile

Wiskott-Aldrich syndrome gene therapy - Genethon

Alternative Names: Ex vivo gene therapy for Wiskott-Aldrich Syndrome (WAS) - Genethon; Lentiviral vector containing the human Wiskott-Aldrich syndrome protein gene - Genethon; WAS gene therapy - Genethon

Latest Information Update: 21 Sep 2015

Price : $50

At a glance

  • Originator Genethon
  • Developer Childrens Hospital Boston; Genethon
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Wiskott-Aldrich syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Wiskott-Aldrich syndrome

Most Recent Events

  • 21 Sep 2015 Phase I/II development is ongoing in USA, France and United Kingdom
  • 21 Apr 2015 Interim efficacy data from a phase I/II trial in Wiskott-Aldrich syndrome released by Genethon
  • 01 Sep 2014 Genethon initiates a long term safety follow up trial for Wiskott-Aldrich Syndrome in France and United Kingdom (NCT02333760)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top